不列颠哥伦比亚省老年经典型霍奇金淋巴瘤患者的结局
该研究基于不列颠哥伦比亚省1961至2019年744例新诊断老年(≥60岁)经典型霍奇金淋巴瘤患者的人群分析,比较各十年间生存变化;中位随访9年,5年疾病特异性生存和总生存按十年比较均改善(均P<.001),近20年保持稳定。现代管理时代(2000年至今)401例中361例(90%)接受积极治疗,5年总生存60%;接受治愈性治疗者5年无进展生存、总生存和疾病特异性生存分别为60%、65%和76%,60至69岁组优于70至79岁组和≥80岁组。博来霉素肺毒性发生于58/279例(21%),其中38%发生在第1或第2周期后。
要点
- 老年cHL患者5年疾病特异性生存和总生存按十年比较均改善(均P<.001),近20年保持稳定(DSS P=.35;OS P=.26)。
- 现代管理时代接受治愈性治疗者5年PFS、OS、DSS分别为60%、65%、76%,60至69岁组优于70至79岁组和≥80岁组(均P<.05)。
- 博来霉素肺毒性发生于58/279例(21%),38%发生在第1或第2周期后,占治疗相关死亡的8/20(40%)。
核心结论
- 近几十年来老年cHL患者结局有所改善,但≥70岁患者在现代治疗时代结局仍差。
- 治疗相关毒性仍是重要问题,作者认为大多数患者应避免使用博来霉素。
研究设计与样本
- 基于人群的分析,纳入不列颠哥伦比亚省1961至2019年新诊断的744例年龄≥60岁经典型霍奇金淋巴瘤患者。
- 中位随访9年,按十年比较5年疾病特异性生存和总生存变化。
- 现代管理时代(2000年至今)401例中361例(90%)接受积极治疗,其中327例接受治愈性治疗。
主要发现
- 5年DSS和OS按十年比较均改善(均P<.001),近20年保持稳定(DSS P=.35;OS P=.26)。
- 现代管理时代接受积极治疗者5年OS为60%。
- 接受治愈性治疗者(n=327)5年PFS、OS、DSS分别为60%、65%、76%。
- 60至69岁组5年PFS、OS、DSS分别为72%、77%、83%,优于70至79岁组的54%、57%、70%和≥80岁组的28%、39%、63%(均P<.05)。
- 博来霉素治疗者中肺毒性发生于58/279例(21%),其中22/58例(38%)发生在第1或第2周期后,占治疗相关死亡的8/20(40%)。
临床怎么用
- 作者认为大多数患者应避免使用博来霉素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcomes in older adults with classic Hodgkin lymphoma (cHL) have traditionally been poor, in part, related to poor tolerance to standard chemotherapy. Herein, we evaluated the survival of patients with cHL aged ≥60 years in British Columbia in a population-based analysis. From 1961 to 2019, 744 patients with newly diagnosed cHL were identified. With a median follow-up of 9 years, 5-year disease-specific survival (DSS) and overall survival (OS) have improved by decade comparison (both P < .001), remaining stable in the past 20 years (DSS, P = .35; OS, P = .26). In the modern management era (2000-present), 361 of 401 patients (90%) received active therapy for cHL and had a 5-year OS of 60%. For those who received curative-intent therapy (n = 327), the 5-year progression-free survival (PFS), OS, and DSS were 60%, 65%, and 76%, respectively, and estimates were superior in those who were 60 to 69 years of age (72%, 77%, and 83%, respectively) compared with those who were 70 to 79 years of age (54%, 57%, and 70%, respectively) and ≥80 years of age (28%, 39%, and 63%, respectively) (P < .05 for all). Overall, pulmonary toxicity occurred in 58 of 279 patients (21%) treated with bleomycin, with 22 of 58 (38%) occurring after cycles 1 or 2, accounting for 8 of 20 (40%) treatment-related deaths. Outcomes in older adults with cHL have improved in recent decades; however, they remain poor for those aged ≥70 years, even in the modern treatment era. Furthermore, treatment-related toxicity remains a significant concern and use of bleomycin should be avoided in most patients.
引用
- Cheng PTM, Villa D, Gerrie AS, et al. The outcome of older adults with classic Hodgkin lymphoma in British Columbia. Blood Adv. 2022. PMID: 36075016. doi:10.1182/bloodadvances.2022008258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。